AKTSAktis Oncology, Inc.Healthcare · Biotechnologyas of 2026-09-16
Horizon

Issued 2026-09-16 at $22.71 · now $22.71 (2026-09-16, +0.0% since)

Based on its own history, a month from the 2026-09-16 close, AKTS has typically landed between $17.77 and $33.01 — a range of −21.7% to +45.4% from the issuance price $22.71.

Range of outcomes in historically similar periods — not a price prediction. Ranges are scored publicly on /methodology.
  • Actual close
  • Typical path (median)
  • Middle 50% of outcomes
  • 90% range

151 overlapping 1 month windows · 2026-01-09 – 2026-08-17 · basis climatology · forecast (batch).

The cone is anchored at the 2026-09-16 issuance close ($22.71) — the price the forecast resolves against on 2026-10-15, not the latest close. The drawn path shape is illustrative (bands widen with √t); every labeled number is real — the anchor, the scored batch p90/IQR endpoints, and the typical move.

Where AKTS has typically landed a month from the 2026-09-16 close of $22.71 — the range is history, not a prediction.

$17.77worst · -21.7%$33.01best · +45.4%
  • now $22.71 (+0.0%)
  • typicalThe typical outcome — half of similar past periods did better and half did worse (not an average, so a few wild periods don't skew it). $23.07 (+1.6%)
  • middle 50%The central range of outcomes — half of similar past periods landed inside it, a quarter finished above, a quarter below. $20.6–$25.54
  • 90% rangeA nine-in-ten range — in about nine of every ten similar past periods the outcome stayed within these bounds. $17.77–$33.01
Actual 1-month windows behind the coneiEvery overlapping 1-month window in this security's own price history was ranked by realized return; shown are the 3 worst and 3 best of 151 windows spanning 2026-01-09 to 2026-09-16. Not cherry-picked — these are the extremes of the full sample. Max drop / max rise are the deepest and highest points reached within each window. See /methodology.
StartReturnMax dropMax rise
3 worst
2026-07-02−30.0%−30.5%+0.0%
2026-06-30−28.6%−30.5%+0.0%
2026-07-01−28.6%−28.6%+2.8%
3 best
2026-06-01+58.6%−4.6%+65.5%
2026-06-02+56.8%−8.3%+59.1%
2026-05-29+55.4%−10.4%+55.4%

151 overlapping windows · 2026-01-09 – 2026-09-16 · not cherry-picked

Reported insider & political trades

Every Form 4 the people closest to this company have filed with the SEC — plotted against the share price, aggregated by month, and shown with the gap between when each trade happened and when it was disclosed. A public record, not advice.

Share price & reported tradesMonthly open-market valueReporting lag — trade date to filing date2026-092026-082026-072026-062026-052026-042026-032026-022026-012025-122025-112025-102025-092025-08$32$152026-07-20: 2 insider sales, $119K — Herrmann Ken …2026-07-17: 1 insider sale, $77K — Herrmann Ken2026-07-08: 6 insider sales, $2.8M — Czibere Akos, Ron-Bigger Shulamit …2026-01-12: 9 insider purchases, $114.3M — EcoR1 Capital, LLC, GADICKE ANSBERT, MPM BIOVENTURES 2018, L.P., Vida Ventures II, LLC …2026-01: 9 open-market purchases, $114.3M2026-07: 9 open-market sales, $3.0M↑ buys↓ salesdirector Herrmann Ken — Sale on 2026-07-20, filed 1 day after the tradedirector Herrmann Ken — Sale on 2026-07-20, filed 1 day after the tradedirector Herrmann Ken — Sale on 2026-07-17, filed 3 days after the tradeofficer Czibere Akos — Sale on 2026-07-08, filed 2 days after the tradeofficer Ron-Bigger Shulamit — Sale on 2026-07-08, filed 2 days after the tradeofficer Ron-Bigger Shulamit — Sale on 2026-07-08, filed 2 days after the tradeofficer Czibere Akos — Sale on 2026-07-08, filed 2 days after the tradeofficer Czibere Akos — Sale on 2026-07-08, filed 2 days after the tradeofficer Ron-Bigger Shulamit — Sale on 2026-07-08, filed 2 days after the tradedirector EcoR1 Capital, LLC — Purchase on 2026-01-12, filed same dayother GADICKE ANSBERT — Purchase on 2026-01-12, filed 2 days after the tradeother MPM BIOVENTURES 2018, L.P. — Purchase on 2026-01-12, filed 2 days after the tradetenPercentOwner Vida Ventures II, LLC — Purchase on 2026-01-12, filed same daydirector Kim Helen Susan — Purchase on 2026-01-12, filed same daydirector Foley Todd — Purchase on 2026-01-12, filed 2 days after the tradedirector EcoR1 Capital, LLC — Purchase on 2026-01-12, filed same daydirector Kim Helen Susan — Purchase on 2026-01-12, filed same daytenPercentOwner Vida Ventures II, LLC — Purchase on 2026-01-12, filed same day
DatePersonRoleActionShares @ priceValueOwnership Δvs S&P 1mvs S&P 6mOwned afterFiling
2026-07-20Herrmann KendirectorSale3,506 @ $24.56$86K−72.2% of holding+0.9%not yet — horizon still open1,350Form 4 · filed 1 day after the trade
2026-07-20Herrmann KendirectorSale1,350 @ $24.56$33K−100.0% of holding+0.9%not yet — horizon still open0Form 4 · filed 1 day after the trade
2026-07-17Herrmann KendirectorSale3,065 @ $25.21$77K−100.0% of holding−4.6%not yet — horizon still open0Form 4 · filed 3 days after the trade
2026-07-08Czibere AkosofficerSale30,829 @ $27.95$862K−87.6% of holding−21.4%not yet — horizon still open4,371Form 4 · filed 2 days after the trade
2026-07-08Ron-Bigger ShulamitofficerSale30,000 @ $27.94$838K−87.7% of holding−21.4%not yet — horizon still open4,200Form 4 · filed 2 days after the trade
2026-07-08Ron-Bigger ShulamitofficerSale15,800 @ $27.13$429K−31.6% of holding−21.4%not yet — horizon still open34,200Form 4 · filed 2 days after the trade
2026-07-08Czibere AkosofficerSale14,800 @ $27.13$401K−29.6% of holding−21.4%not yet — horizon still open35,200Form 4 · filed 2 days after the trade
2026-07-08Czibere AkosofficerSale4,371 @ $28.71$125K−100.0% of holding−21.4%not yet — horizon still open0Form 4 · filed 2 days after the trade
2026-07-08Ron-Bigger ShulamitofficerSale4,200 @ $28.75$121K−100.0% of holding−21.4%not yet — horizon still open0Form 4 · filed 2 days after the trade
2026-01-12EcoR1 Capital, LLCdirectorPurchase2,077,779 @ $18.00$37.4M+91.5% of holding−16.5%+10.4%4,348,658Form 4 · filed same day
2026-01-12GADICKE ANSBERTotherPurchase1,112,777 @ $18.00$20.0M+12.2% of holding−16.5%+10.4%10,260,064Form 4 · filed 2 days after the trade
2026-01-12MPM BIOVENTURES 2018, L.P.otherPurchase1,112,777 @ $18.00$20.0M+12.2% of holding−16.5%+10.4%10,260,064Form 4 · filed 2 days after the trade
2026-01-12Vida Ventures II, LLCtenPercentOwnerPurchase812,455 @ $18.00$14.6M+16.7% of holding−16.5%+10.4%5,671,825Form 4 · filed same day
2026-01-12Kim Helen SusandirectorPurchase812,455 @ $18.00$14.6M+16.7% of holding−16.5%+10.4%5,671,825Form 4 · filed same day
2026-01-12Foley TodddirectorPurchase232,870 @ $18.00$4.2M+5.8% of holding−16.5%+10.4%4,235,403Form 4 · filed 2 days after the trade
2026-01-12EcoR1 Capital, LLCdirectorPurchase144,443 @ $18.00$2.6M+71.2% of holding−16.5%+10.4%347,305Form 4 · filed same day
2026-01-12Kim Helen SusandirectorPurchase22,545 @ $18.00$406K+16.7% of holding−16.5%+10.4%157,387Form 4 · filed same day
2026-01-12Vida Ventures II, LLCtenPercentOwnerPurchase22,545 @ $18.00$406K+16.7% of holding−16.5%+10.4%157,387Form 4 · filed same day

The vs-S&P columns are a labeled look-back on what the stock did after each filing, measured against the index over the same window. Descriptive history, not a claim about the person or a reason to trade.

119 award / exercise / gift records — not counted as purchases

Awards, option exercises, gifts and tax-withholding disposals are shown separately and never counted as open-market purchases or sales — they carry no conviction information.

DatePersonRoleActionSharesOwned afterFiling
2026-07-20Herrmann KendirectorOption exercise1,3504,856Form 4
2026-07-20Herrmann KendirectorOption exercise3,5063,506Form 4
2026-07-20Herrmann KendirectorOption exercise1,35018,364Form 4
2026-07-20Herrmann KendirectorOption exercise3,5060Form 4
2026-07-17Herrmann KendirectorOption exercise3,0653,065Form 4
2026-07-17Herrmann KendirectorOption exercise3,0653,506Form 4
2026-07-08Czibere AkosofficerOption exercise50,00050,000Form 4
2026-07-08Ron-Bigger ShulamitofficerOption exercise50,00050,000Form 4
2026-07-08Czibere AkosofficerOption exercise50,000221,218Form 4
2026-07-08Ron-Bigger ShulamitofficerOption exercise50,000217,888Form 4
2026-04-15Gormley GlenndirectorAward / grant37,86637,866Form 4
2026-01-12Vida Ventures II, LLCtenPercentOwnerConversion411,7500Form 4
2026-01-12Vida Ventures II, LLCtenPercentOwnerConversion14,838,2500Form 4
2026-01-12GADICKE ANSBERTotherConversion5,000,0000Form 4
2026-01-12GADICKE ANSBERTotherConversion22,500,0000Form 4
2026-01-12GADICKE ANSBERTotherConversion6,000,0000Form 4
2026-01-12Segal Lloyd MitchelldirectorConversion24,6870Form 4
2026-01-12Foley TodddirectorConversion2,272,7270Form 4
2026-01-12Foley TodddirectorConversion10,227,2730Form 4
2026-01-12Foley TodddirectorConversion2,727,2730Form 4
2026-01-12Kim Helen SusandirectorConversion3,648,7500Form 4
2026-01-12Segal Lloyd MitchelldirectorConversion50,0000Form 4
2026-01-12Kim Helen SusandirectorConversion101,2500Form 4
2026-01-12Vida Ventures II, LLCtenPercentOwnerConversion101,2500Form 4
2026-01-12Kim Helen SusandirectorConversion411,7500Form 4
2026-01-12Kim Helen SusandirectorConversion14,838,2500Form 4
2026-01-12Vida Ventures II, LLCtenPercentOwnerConversion3,648,7500Form 4
2026-01-12MPM BIOVENTURES 2018, L.P.otherConversion5,000,0000Form 4
2026-01-12MPM BIOVENTURES 2018, L.P.otherConversion22,500,0000Form 4
2026-01-12MPM BIOVENTURES 2018, L.P.otherConversion6,000,0000Form 4
2026-01-12GADICKE ANSBERTotherConversion1,314,2621,655,971Form 4
2026-01-12MPM BIOVENTURES 2018, L.P.otherConversion1,314,2621,655,971Form 4
2026-01-12MPM BIOVENTURES 2018, L.P.otherConversion5,914,1977,570,168Form 4
2026-01-12MPM BIOVENTURES 2018, L.P.otherConversion1,577,1199,147,287Form 4
2026-01-12MPM BIOVENTURES 2018, L.P.otherConversion1,314,2621,655,971Form 4
2026-01-12MPM BIOVENTURES 2018, L.P.otherConversion5,914,1977,570,168Form 4
2026-01-12MPM BIOVENTURES 2018, L.P.otherConversion1,577,1199,147,287Form 4
2026-01-12MPM BIOVENTURES 2018, L.P.otherConversion1,314,2621,655,971Form 4
2026-01-12MPM BIOVENTURES 2018, L.P.otherConversion5,914,1977,570,168Form 4
2026-01-12MPM BIOVENTURES 2018, L.P.otherConversion1,577,1199,147,287Form 4

Source: SEC Form 4 filings. Each row links to its original filing.

Across 2012–2021, stocks where a CEO, C-suite officer, or director had recently made an open-market common-stock purchase ran about +28 bp per month above the universe average (n=34,268 stock-weeks). A historical tendency, not a prediction.

Congressional disclosures

No congressional trades disclosed for this company.

Research tool, not investment advice — historical frequencies, not recommendations. A product of Marovel Technologies LLC. Full terms.